EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY-NC 4.0

Decision‐Making Criteria and Methods for Initiating Late‐Stage Clinical Trials in Drug Development From a Multi‐Stakeholder Perspective: A Scoping Review

Ce Jiang iD, Céline Beji, Sonia Zebachi iD, Ghinwa Y Hayek iD, Aysun Cetinyurek-Yavuz iD, Muhammad Bergas N Fayyad iD, Laura Rodwell iD, Kit C B Roes iD, Billy Amzal, Christoph Gerlinger iD, Raphaël Porcher iD, Julien Tanniou iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3566 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Ce Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Quinten Health, Paris, France. Hauptthemen laut MEDLINE: Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Decision Making, Drug Development. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The decision‐making process in drug development involves “go/no‐go” decisions, particularly at the transition from early to late‐stage trials. While the decisions are solely made by drug developers, they must take into account the perspectives of multiple stakeholders—such as regulatory agencies, HTA bodies, payers, patients, and ethics committees—to ensure well‐informed and robust decision‐making. These perspectives influence key considerations, including resource allocation, risk mitigation, regulatory compliance, etc. To support this process, quantitative methodologies, including Bayesian and hybrid frequentist‐Bayesian approaches, have been introduced to improve decision‐making. However, these methodologies often do not fully account for the diverse priorities and needs of all stakeholders. This scoping review examines criteria and methods used in decision‐making at the phase II to III transition, with a focus on broadening the probability of success (PoS) concept beyond efficacy alone. Our review explores PoS for different success definitions, such as regulatory approval, market access, financial viability, and competitive performance. Key themes include decision criteria selection, trial design optimization, utility‐based approaches, financial metrics, and multi‐stakeholder considerations in decision‐making. Our findings highlight both the limitations of current methodologies and potential paths forward, including the integration of real‐world data (RWD) and advanced analytics. This work complements a companion manuscript by Cetinyurek‐Yavuz et al . (2025) providing a detailed review of PoS methodologies focused solely on efficacy, specifically PoS for achieving statistical significance in phase III studies, including definitions, terminologies, and analytical approaches. Together, these studies provide a foundation for advancing late‐stage trial decisions toward a more balanced, data‐driven, and stakeholder‐aligned approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDecision MakingDrug DevelopmentStakeholder ParticipationHumansBayes TheoremResearch Design

Autor:innen und Institutionen

  • Quinten Health, Paris, France.
  • Paris Cité University, Paris, France.
  • Radboud University Medical Center, Nijmegen, The Netherlands.
  • Bayer AG, Statistics & Data Insights, Berlin, Germany.

ORCID-Profile: Ce Jiang, Sonia Zebachi, Ghinwa Y Hayek, Aysun Cetinyurek-Yavuz, Muhammad Bergas N Fayyad, Laura Rodwell, Kit C B Roes, Christoph Gerlinger, Raphaël Porcher, Julien Tanniou

Zitieren

APA

Jiang, C., Beji, C., Zebachi, S., Hayek, G. Y., Cetinyurek-Yavuz, A., Fayyad, M. B. N., Rodwell, L., Roes, K. C. B., Amzal, B., Gerlinger, C., Porcher, R., & Tanniou, J. (2025). Decision‐Making Criteria and Methods for Initiating Late‐Stage Clinical Trials in Drug Development From a Multi‐Stakeholder Perspective: A Scoping Review. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3566

Vancouver

Jiang C, Beji C, Zebachi S, Hayek GY, Cetinyurek-Yavuz A, Fayyad MBN, et al. Decision‐Making Criteria and Methods for Initiating Late‐Stage Clinical Trials in Drug Development From a Multi‐Stakeholder Perspective: A Scoping Review. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3566

BibTeX
@article{Jiang2025,
  author = {Jiang, Ce and Beji, Céline and Zebachi, Sonia and Hayek, Ghinwa Y and Cetinyurek-Yavuz, Aysun and Fayyad, Muhammad Bergas N and Rodwell, Laura and Roes, Kit C B and Amzal, Billy and Gerlinger, Christoph and Porcher, Raphaël and Tanniou, Julien},
  title = {Decision‐Making Criteria and Methods for Initiating Late‐Stage Clinical Trials in Drug Development From a Multi‐Stakeholder Perspective: A Scoping Review},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3566}
}
Kostenlos starten →